{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T05:19:26Z","timestamp":1784956766014,"version":"3.55.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T00:00:00Z","timestamp":1672099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T00:00:00Z","timestamp":1672099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>As SARS-CoV-2 Omicron and other variants of concern (VOCs) continue spreading worldwide, development of antibodies and vaccines to confer broad and protective activity is a global priority. Here, we report on the identification of a special group of nanobodies from immunized alpaca with potency against diverse VOCs including Omicron subvariants BA.1, BA.2 and BA.4\/5, SARS-CoV-1, and major sarbecoviruses. Crystal structure analysis of one representative nanobody, 3-2A2-4, discovers a highly conserved epitope located between the cryptic and the outer face of the receptor binding domain (RBD), distinctive from the receptor ACE2 binding site. Cryo-EM and biochemical evaluation reveal that 3-2A2-4 interferes structural alteration of RBD required for ACE2 binding. Passive delivery of 3-2A2-4 protects K18-hACE2 mice from infection of authentic SARS-CoV-2 Delta and Omicron. Identification of these unique nanobodies will inform the development of next generation antibody therapies and design of pan-sarbecovirus vaccines.<\/jats:p>","DOI":"10.1038\/s41467-022-35642-2","type":"journal-article","created":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T06:02:48Z","timestamp":1672120968000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4\/5 and diverse sarbecoviruses"],"prefix":"10.1038","volume":"13","author":[{"given":"Mingxi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6097-4099","authenticated-orcid":false,"given":"Zhen Qin","family":"Aw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingtai","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1148-0444","authenticated-orcid":false,"given":"Junxian","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6824-7446","authenticated-orcid":false,"given":"Yiling","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6704-9130","authenticated-orcid":false,"given":"Yi Hao","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sisi","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1703-3848","authenticated-orcid":false,"given":"Senyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9366-1470","authenticated-orcid":false,"given":"Jiwan","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8040-7913","authenticated-orcid":false,"given":"Ruoke","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay Zengjun","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanling","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3544-1389","authenticated-orcid":false,"given":"Zheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1673-6819","authenticated-orcid":false,"given":"Justin Jang Hann","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinquan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4931-509X","authenticated-orcid":false,"given":"Linqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,27]]},"reference":[{"key":"35642_CR1","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/S0140-6736(22)00090-3","volume":"399","author":"C Kuhlmann","year":"2022","unstructured":"Kuhlmann, C., Ck, M. & Claassen, M. Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose. Lancet 399, 628\u2013628 (2022).","journal-title":"Lancet"},{"key":"35642_CR2","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1056\/NEJMoa2116597","volume":"386","author":"DW Eyre","year":"2022","unstructured":"Eyre, D. W. et al. Effect of covid-19 vaccination on transmission of alpha and delta variants. N. Engl. J. Med. 386, 744\u2013756 (2022).","journal-title":"N. Engl. J. Med."},{"key":"35642_CR3","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41591-021-01413-7","volume":"27","author":"T Kustin","year":"2021","unstructured":"Kustin, T. et al. Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. Nat. Med. 27, 1379 (2021).","journal-title":"Nat. Med."},{"key":"35642_CR4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1056\/NEJMoa2203965","volume":"387","author":"HN Altarawneh","year":"2022","unstructured":"Altarawneh, H. N. et al. Effects of previous infection and vaccination on symptomatic omicron infections. N. Engl. J. Med. 387, 21\u201334 (2022).","journal-title":"N. Engl. J. Med."},{"key":"35642_CR5","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41586-021-03398-2","volume":"593","author":"PF Wang","year":"2021","unstructured":"Wang, P. F. et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 593, 130 (2021).","journal-title":"Nature"},{"key":"35642_CR6","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/s41586-021-04085-y","volume":"600","author":"C Lucas","year":"2021","unstructured":"Lucas, C. et al. Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity. Nature 600, 523 (2021).","journal-title":"Nature"},{"key":"35642_CR7","doi-asserted-by":"publisher","unstructured":"Liu, L. H. et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature, https:\/\/doi.org\/10.1038\/s41586-021-04388-0 (2021).","DOI":"10.1038\/s41586-021-04388-0"},{"key":"35642_CR8","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1056\/NEJMc2119236","volume":"386","author":"A Rossler","year":"2022","unstructured":"Rossler, A., Riepler, L., Bante, D., von Laer, D. & Kimpel, J. SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons. N. Engl. J. Med. 386, 698 (2022).","journal-title":"N. Engl. J. Med."},{"key":"35642_CR9","doi-asserted-by":"publisher","unstructured":"Carreno, J. M. et al. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature, https:\/\/doi.org\/10.1038\/s41586-022-04399-5 (2021).","DOI":"10.1038\/s41586-022-04399-5"},{"key":"35642_CR10","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1016\/j.immuni.2021.06.003","volume":"54","author":"RK Wang","year":"2021","unstructured":"Wang, R. K. et al. Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species. Immunity 54, 1611 (2021).","journal-title":"Immunity"},{"key":"35642_CR11","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","volume":"602","author":"Y Cao","year":"2022","unstructured":"Cao, Y. et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 602, 657\u2013663 (2022).","journal-title":"Nature"},{"key":"35642_CR12","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/s41586-021-04386-2","volume":"602","author":"E Cameroni","year":"2022","unstructured":"Cameroni, E. et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature 602, 664\u2013670 (2022).","journal-title":"Nature"},{"key":"35642_CR13","doi-asserted-by":"publisher","unstructured":"Halfmann, P. J. et al. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. Nature, https:\/\/doi.org\/10.1038\/s41586-022-04441-6 (2022).","DOI":"10.1038\/s41586-022-04441-6"},{"key":"35642_CR14","doi-asserted-by":"publisher","unstructured":"Shuai, H. et al. Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron. Nature https:\/\/doi.org\/10.1038\/s41586-022-04442-5 (2022).","DOI":"10.1038\/s41586-022-04442-5"},{"key":"35642_CR15","doi-asserted-by":"publisher","unstructured":"Hui, K. P. Y. et al. SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo. Nature https:\/\/doi.org\/10.1038\/s41586-022-04479-6 (2022).","DOI":"10.1038\/s41586-022-04479-6"},{"key":"35642_CR16","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.chom.2022.01.005","volume":"30","author":"S Cele","year":"2022","unstructured":"Cele, S. et al. SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape. Cell Host Microbe 30, 154\u2013162.e155 (2022).","journal-title":"Cell Host Microbe"},{"key":"35642_CR17","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.jgg.2021.12.003","volume":"48","author":"C Wei","year":"2021","unstructured":"Wei, C. et al. Evidence for a mouse origin of the SARS-CoV-2 Omicron variant. J. Genet Genomics 48, 1111\u20131121 (2021).","journal-title":"J. Genet Genomics"},{"key":"35642_CR18","doi-asserted-by":"publisher","unstructured":"Tegally, H. et al. Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. Nat Med, https:\/\/doi.org\/10.1038\/s41591-022-01911-2 (2022).","DOI":"10.1038\/s41591-022-01911-2"},{"key":"35642_CR19","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1016\/j.cell.2022.06.005","volume":"185","author":"A Tuekprakhon","year":"2022","unstructured":"Tuekprakhon, A. et al. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell 185, 2422\u20132433.e2413 (2022).","journal-title":"Cell"},{"key":"35642_CR20","doi-asserted-by":"publisher","first-page":"eabn8897","DOI":"10.1126\/science.abn8897","volume":"376","author":"T Zhou","year":"2022","unstructured":"Zhou, T. et al. Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529. Science 376, eabn8897 (2022).","journal-title":"Science"},{"key":"35642_CR21","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41586-021-04245-0","volume":"602","author":"Y Liu","year":"2022","unstructured":"Liu, Y. et al. The N501Y spike substitution enhances SARS-CoV-2 infection and transmission. Nature 602, 294\u2013299 (2022).","journal-title":"Nature"},{"key":"35642_CR22","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.1016\/j.cell.2021.04.025","volume":"184","author":"X Deng","year":"2021","unstructured":"Deng, X. et al. Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. Cell 184, 3426\u20133437.e3428 (2021).","journal-title":"Cell"},{"key":"35642_CR23","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41586-021-03777-9","volume":"596","author":"D Planas","year":"2021","unstructured":"Planas, D. et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature 596, 276\u2013280 (2021).","journal-title":"Nature"},{"key":"35642_CR24","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1126\/science.abl9463","volume":"374","author":"J Zhang","year":"2021","unstructured":"Zhang, J. et al. Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant. Science 374, 1353\u20131360 (2021).","journal-title":"Science"},{"key":"35642_CR25","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/s41591-021-01270-4","volume":"27","author":"X Xie","year":"2021","unstructured":"Xie, X. et al. Neutralization of SARS-CoV-2 spike 69\/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nat. Med. 27, 620\u2013621 (2021).","journal-title":"Nat. Med."},{"key":"35642_CR26","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.chom.2021.01.014","volume":"29","author":"ZM Liu","year":"2021","unstructured":"Liu, Z. M. et al. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host Microbe 29, 477 (2021).","journal-title":"Cell Host Microbe"},{"key":"35642_CR27","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41586-021-03324-6","volume":"592","author":"Z Wang","year":"2021","unstructured":"Wang, Z. et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature 592, 616\u2013622 (2021).","journal-title":"Nature"},{"key":"35642_CR28","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","volume":"19","author":"WT Harvey","year":"2021","unstructured":"Harvey, W. T. et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol 19, 409\u2013424 (2021).","journal-title":"Nat. Rev. Microbiol"},{"key":"35642_CR29","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1016\/j.cell.2021.03.028","volume":"184","author":"M McCallum","year":"2021","unstructured":"McCallum, M. et al. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell 184, 2332\u20132347.e2316 (2021).","journal-title":"Cell"},{"key":"35642_CR30","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1126\/science.abc6952","volume":"369","author":"X Chi","year":"2020","unstructured":"Chi, X. et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science 369, 650\u2013655 (2020).","journal-title":"Science"},{"key":"35642_CR31","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1016\/j.cell.2021.03.029","volume":"184","author":"N Suryadevara","year":"2021","unstructured":"Suryadevara, N. et al. Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein. Cell 184, 2316\u20132331.e2315 (2021).","journal-title":"Cell"},{"key":"35642_CR32","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","volume":"82","author":"S Muyldermans","year":"2013","unstructured":"Muyldermans, S. Nanobodies: natural single-domain antibodies. Annu Rev. Biochem 82, 775\u2013797 (2013).","journal-title":"Annu Rev. Biochem"},{"key":"35642_CR33","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1146\/annurev-animal-021419-083831","volume":"9","author":"S Muyldermans","year":"2021","unstructured":"Muyldermans, S. Applications of nanobodies. Annu Rev. Anim. Biosci. 9, 401\u2013421 (2021).","journal-title":"Annu Rev. Anim. Biosci."},{"key":"35642_CR34","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa1806311","volume":"380","author":"M Scully","year":"2019","unstructured":"Scully, M. et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N. Engl. J. Med 380, 335\u2013346 (2019).","journal-title":"N. Engl. J. Med"},{"key":"35642_CR35","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.cell.2020.05.047","volume":"181","author":"D Wrapp","year":"2020","unstructured":"Wrapp, D. et al. Structural basis for potent neutralization of betacoronaviruses by single-domain camelid antibodies. Cell 181, 1436\u20131441 (2020).","journal-title":"Cell"},{"key":"35642_CR36","doi-asserted-by":"publisher","unstructured":"Schepens, B. et al. An affinity-enhanced, broadly neutralizing heavy chain-only antibody protects against SARS-CoV-2 infection in animal models. Sci. Transl. Med. 13, https:\/\/doi.org\/10.1126\/scitranslmed.abi7826 (2021).","DOI":"10.1126\/scitranslmed.abi7826"},{"key":"35642_CR37","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1126\/science.abe3255","volume":"370","author":"M Schoof","year":"2020","unstructured":"Schoof, M. et al. An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike. Science 370, 1473\u20131479 (2020).","journal-title":"Science"},{"key":"35642_CR38","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1126\/science.abe4747","volume":"370","author":"YF Xiang","year":"2020","unstructured":"Xiang, Y. F. et al. Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2. Science 370, 1479\u20131484 (2020).","journal-title":"Science"},{"key":"35642_CR39","doi-asserted-by":"publisher","unstructured":"Sun, D. P. et al. Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes. Nat. Commun. 12, ARTN 4676 https:\/\/doi.org\/10.1038\/s41467-021-24963-3 (2021).","DOI":"10.1038\/s41467-021-24963-3"},{"key":"35642_CR40","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41586-021-03676-z","volume":"595","author":"JL Xu","year":"2021","unstructured":"Xu, J. L. et al. Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants. Nature 595, 278\u2012+ (2021).","journal-title":"Nature"},{"key":"35642_CR41","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1038\/s41594-020-00527-9","volume":"27","author":"JD Huo","year":"2020","unstructured":"Huo, J. D. et al. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. Nat. Struct. Mol. Biol. 27, 1094\u20131094 (2020).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"35642_CR42","doi-asserted-by":"publisher","unstructured":"Hanke, L. et al. An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction. Nat Commun 11, ARTN 4420 https:\/\/doi.org\/10.1038\/s41467-020-18174-5 (2020).","DOI":"10.1038\/s41467-020-18174-5"},{"key":"35642_CR43","doi-asserted-by":"publisher","first-page":"691\u2012+","DOI":"10.1126\/science.abe6230","volume":"371","author":"PA Koenig","year":"2021","unstructured":"Koenig, P. A. et al. Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape. Science 371, 691\u2012+ (2021).","journal-title":"Science"},{"key":"35642_CR44","doi-asserted-by":"publisher","unstructured":"Pymm, P. et al. Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice. P Natl Acad Sci USA 118, ARTN e2101918118 https:\/\/doi.org\/10.1073\/pnas.2101918118 (2021).","DOI":"10.1073\/pnas.2101918118"},{"key":"35642_CR45","doi-asserted-by":"publisher","unstructured":"Yang, Z. L. et al. A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants. Signal Transduct Tar 6, ARTN 378 https:\/\/doi.org\/10.1038\/s41392-021-00810-1 (2021).","DOI":"10.1038\/s41392-021-00810-1"},{"key":"35642_CR46","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.chom.2020.04.023","volume":"27","author":"Y Wu","year":"2020","unstructured":"Wu, Y. et al. Identification of human single-domain antibodies against SARS-CoV-2. Cell Host Microbe 27, 891\u2013898 e895 (2020).","journal-title":"Cell Host Microbe"},{"key":"35642_CR47","doi-asserted-by":"publisher","first-page":"111004","DOI":"10.1016\/j.celrep.2022.111004","volume":"39","author":"Y Xiang","year":"2022","unstructured":"Xiang, Y. et al. Superimmunity by pan-sarbecovirus nanobodies. Cell Rep. 39, 111004 (2022).","journal-title":"Cell Rep."},{"key":"35642_CR48","doi-asserted-by":"publisher","first-page":"697074","DOI":"10.3389\/fimmu.2021.697074","volume":"12","author":"M Li","year":"2021","unstructured":"Li, M. et al. Single-dose immunization with a chimpanzee adenovirus-based vaccine induces sustained and protective immunity against SARS-CoV-2 infection. Front Immunol. 12, 697074 (2021).","journal-title":"Front Immunol."},{"key":"35642_CR49","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1038\/s41590-022-01222-1","volume":"23","author":"WT He","year":"2022","unstructured":"He, W. T. et al. Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses. Nat. Immunol. 23, 960\u2013970 (2022).","journal-title":"Nat. Immunol."},{"key":"35642_CR50","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1016\/j.cell.2021.04.032","volume":"184","author":"JF Scheid","year":"2021","unstructured":"Scheid, J. F. et al. B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV. Cell 184, 3205 (2021).","journal-title":"Cell"},{"key":"35642_CR51","doi-asserted-by":"publisher","unstructured":"Zhao, F. et al. Broadening a SARS-CoV-1 neutralizing antibody for potent SARS-CoV-2 neutralization through directed evolution. bioRxiv, 2021.2005.2029.443900, https:\/\/doi.org\/10.1101\/2021.05.29.443900 (2021).","DOI":"10.1101\/2021.05.29.443900"},{"key":"35642_CR52","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1126\/science.abb7269","volume":"368","author":"M Yuan","year":"2020","unstructured":"Yuan, M. et al. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science 368, 630\u2012+ (2020).","journal-title":"Science"},{"key":"35642_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10897-4","volume":"10","author":"H Zhou","year":"2019","unstructured":"Zhou, H. et al. Structural definition of a neutralization epitope on the N-terminal domain of MERS-CoV spike glycoprotein. Nat. Commun. 10, 3068 (2019).","journal-title":"Nat. Commun."},{"key":"35642_CR54","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1126\/science.abh2315","volume":"374","author":"KM Hastie","year":"2021","unstructured":"Hastie, K. M. et al. Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: a global consortium study. Science 374, 472 (2021).","journal-title":"Science"},{"key":"35642_CR55","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41586-020-2380-z","volume":"584","author":"B Ju","year":"2020","unstructured":"Ju, B. et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature 584, 115 (2020).","journal-title":"Nature"},{"key":"35642_CR56","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.cell.2022.01.019","volume":"185","author":"Z Cui","year":"2022","unstructured":"Cui, Z. et al. Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron. Cell 185, 860\u2013871 e813 (2022).","journal-title":"Cell"},{"key":"35642_CR57","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/s41586-022-04581-9","volume":"604","author":"Q Hong","year":"2022","unstructured":"Hong, Q. et al. Molecular basis of receptor binding and antibody neutralization of Omicron. Nature 604, 546\u2013552 (2022).","journal-title":"Nature"},{"key":"35642_CR58","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.chom.2020.07.002","volume":"28","author":"J Huo","year":"2020","unstructured":"Huo, J. et al. Neutralization of SARS-CoV-2 by destruction of the prefusion spike. Cell Host Microbe 28, 497 (2020).","journal-title":"Cell Host Microbe"},{"key":"35642_CR59","doi-asserted-by":"publisher","unstructured":"Shan, S. S. et al. A potent and protective human neutralizing antibody against SARS-CoV-2 variants. Front Immunol. 12, ARTN 766821 https:\/\/doi.org\/10.3389\/fimmu.2021.766821 (2021).","DOI":"10.3389\/fimmu.2021.766821"},{"key":"35642_CR60","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1126\/science.abd0826","volume":"369","author":"CL Hsieh","year":"2020","unstructured":"Hsieh, C. L. et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science 369, 1501\u20131505 (2020).","journal-title":"Science"},{"key":"35642_CR61","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1126\/science.abc5881","volume":"369","author":"Z Lv","year":"2020","unstructured":"Lv, Z. et al. Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody. Science 369, 1505\u20131509 (2020).","journal-title":"Science"},{"key":"35642_CR62","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1126\/science.abm8143","volume":"375","author":"YJ Park","year":"2022","unstructured":"Park, Y. J. et al. Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry. Science 375, 449 (2022).","journal-title":"Science"},{"key":"35642_CR63","doi-asserted-by":"publisher","first-page":"eabl6251","DOI":"10.1126\/science.abl6251","volume":"375","author":"KG Nabel","year":"2022","unstructured":"Nabel, K. G. et al. Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain. Science 375, eabl6251 (2022).","journal-title":"Science"},{"key":"35642_CR64","doi-asserted-by":"publisher","first-page":"eabj7125","DOI":"10.1126\/scitranslmed.abj7125","volume":"14","author":"DR Martinez","year":"2022","unstructured":"Martinez, D. R. et al. A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice. Sci. Transl. Med. 14, eabj7125 (2022).","journal-title":"Sci. Transl. Med."},{"key":"35642_CR65","doi-asserted-by":"publisher","unstructured":"Fedry, J. et al. Structural insights into the cross-neutralization of SARS-CoV and SARS-CoV-2 by the human monoclonal antibody 47D11. Sci. Adv. 7, ARTN eabf5632 https:\/\/doi.org\/10.1126\/sciadv.abf5632 (2021).","DOI":"10.1126\/sciadv.abf5632"},{"key":"35642_CR66","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41586-021-03817-4","volume":"597","author":"MA Tortorici","year":"2021","unstructured":"Tortorici, M. A. et al. Broad sarbecovirus neutralization by a human monoclonal antibody. Nature 597, 103 (2021).","journal-title":"Nature"},{"key":"35642_CR67","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41586-021-03807-6","volume":"597","author":"TN Starr","year":"2021","unstructured":"Starr, T. N. et al. SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape. Nature 597, 97 (2021).","journal-title":"Nature"},{"key":"35642_CR68","doi-asserted-by":"publisher","unstructured":"Li, T. T. et al. Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants. Nat. Commun. 12, ARTN 5652 https:\/\/doi.org\/10.1038\/s41467-021-25997-3 (2021).","DOI":"10.1038\/s41467-021-25997-3"},{"key":"35642_CR69","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.immuni.2020.10.023","volume":"53","author":"HJ Liu","year":"2020","unstructured":"Liu, H. J. et al. Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity. Immunity 53, 1272 (2020).","journal-title":"Immunity"},{"key":"35642_CR70","doi-asserted-by":"publisher","unstructured":"Jennewein, M. F. et al. Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+subjects. Cell Rep. 36, ARTN 109353 https:\/\/doi.org\/10.1016\/j.celrep.2021.109353 (2021).","DOI":"10.1016\/j.celrep.2021.109353"},{"key":"35642_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27610-z","volume":"13","author":"L Hanke","year":"2022","unstructured":"Hanke, L. et al. A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo. Nat. Commun. 13, 155 (2022).","journal-title":"Nat. Commun."},{"key":"35642_CR72","doi-asserted-by":"publisher","unstructured":"Zhou, P. et al. A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection. Sci. Transl. Med. eabi9215, https:\/\/doi.org\/10.1126\/scitranslmed.abi9215 (2022).","DOI":"10.1126\/scitranslmed.abi9215"},{"key":"35642_CR73","doi-asserted-by":"publisher","first-page":"110210","DOI":"10.1016\/j.celrep.2021.110210","volume":"38","author":"W Li","year":"2022","unstructured":"Li, W. et al. Structural basis and mode of action for two broadly neutralizing antibodies against SARS-CoV-2 emerging variants of concern. Cell Rep. 38, 110210 (2022).","journal-title":"Cell Rep."},{"key":"35642_CR74","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1126\/science.abj3321","volume":"373","author":"D Pinto","year":"2021","unstructured":"Pinto, D. et al. Broad betacoronavirus neutralization by a stem helix-specific human antibody. Science 373, 1109\u20131116 (2021).","journal-title":"Science"},{"key":"35642_CR75","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1056\/NEJMoa2108453","volume":"385","author":"CW Tan","year":"2021","unstructured":"Tan, C. W. et al. Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors. N. Engl. J. Med. 385, 1401\u20131406 (2021).","journal-title":"N. Engl. J. Med."},{"key":"35642_CR76","doi-asserted-by":"publisher","unstructured":"Stamatatos, L. et al. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science, https:\/\/doi.org\/10.1126\/science.abg9175 (2021).","DOI":"10.1126\/science.abg9175"},{"key":"35642_CR77","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41586-022-04778-y","volume":"607","author":"F Muecksch","year":"2022","unstructured":"Muecksch, F. et al. Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost. Nature 607, 128\u2013134 (2022).","journal-title":"Nature"},{"key":"35642_CR78","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","volume":"581","author":"J Lan","year":"2020","unstructured":"Lan, J. et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581, 215\u2013220 (2020).","journal-title":"Nature"},{"key":"35642_CR79","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1093\/bioinformatics\/btu393","volume":"30","author":"Z Gu","year":"2014","unstructured":"Gu, Z., Gu, L., Eils, R., Schlesner, M. & Brors, B. Circlize Implements and enhances circular visualization in R. Bioinformatics 30, 2811\u20132812 (2014).","journal-title":"Bioinformatics"},{"key":"35642_CR80","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1093\/bioinformatics\/btz921","volume":"36","author":"A Tareen","year":"2020","unstructured":"Tareen, A. & Kinney, J. B. Logomaker: beautiful sequence logos in Python. Bioinformatics 36, 2272\u20132274 (2020).","journal-title":"Bioinformatics"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-35642-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-35642-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-35642-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T11:03:31Z","timestamp":1672398211000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-35642-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,27]]},"references-count":80,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["35642"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-35642-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,27]]},"assertion":[{"value":"3 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.C. is an employee of NB BIOLAB Co., Ltd. J.D. is an employee of HplanetBio Co., Ltd. Y.C. is an employee of Hua Bio Co., Ltd. Patent applications have been filed on nanobodies targeting sarbecoviruses. L.Z., M.L., Y.L., J.H., Y.Y., X.S., and Q.Z. are the inventors. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7957"}}